Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: A review

Medical Science Monitor

Volumn 12, Issue 12, 2006, Pages

  Rizzardini, Giuliano ^a   Capetti, Amedeo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Abacavir; Protease inhibitor; Simplification; Triple nucleoside; Viral failure

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; AZL 30002; CHOLESTEROL; CNA 30017; EFAVIRENZ; ESS 40003; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHADONE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ABDOMINAL FAT; BODY FAT; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; LIPODYSTROPHY; METABOLIC PARAMETERS; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VISUAL ANALOG SCALE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HIV INFECTIONS; HIV-1; HUMANS; MULTICENTER STUDIES; MUTATION; RANDOMIZED CONTROLLED TRIALS; SAFETY;

EID: 33845496301     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Barbaro G: Adiponectin and HIV-associated lypodystrophy. Med Sci Monit, 2003; 9(11): LE25-26
2. Carr A, Samaras K, Burton S et al: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998; 12: F51-58
3. Morris AA, Carr A: HIV nucleoside analogues: new adverse effects on mitochondria? Lancet. 1999; 354: 1046-47
4. Carr A, Miller J, Law M, Cooper DA: A syndrome of lipoatrophy, lactic acidaemia and liver disfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS, 2000; 14: F25-32
5. th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005
6. Martinez E, Arnaiz JA, Podzamczer D et al: Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med, 2003; 349: 1036-46
7. Bonjoch A, Paredes R, Galvez J et al: Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr, 2005; 39: 313-16
8. Opravil M, Hirschel B, Lazzarin A et al: A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection. J Infect Dis, 2002; 185: 1251-60
9. Maggiolo F, Ripamonti D, Ravasio L et al: Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis, 2003; 37: 41-49
10. Bucher HC, Kofler A, Nüesch R et al: Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1 infected patients. AIDS, 2003; 17: 2451-59
11. Cherry CL, Lal L, Thompson KA et al: Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr, 2005; 38(3): 263-67
12. Gallant JE, Rodriguez AE, Weinberg WG et al: Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. (ESS30009 Study) J Infect Dis, 2005; 192(11): 1921-30
13. Ochoa de Echaguën A, Arnedo M, Xercavins M et al: Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS, 2005; 19: 1385-91
14. No authors listed: High rate of virologic failure with once-daily ddI/3TC/TDF. IAPAC Mon, 2003; 9(11): 279
15. Opravil M, Baumann D, Chave JP et al: Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS, 2004; 18: 2213-15
16. Katlama C, Fenske S, Gazzard B et al: TRIZAL study: switching from successful HAART to Trizivir™ (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med, 2003; 4: 79-86
17. Clumeck N, Goebel F, Rozenbaum W et al: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS, 2001; 15: 1517-26
18. Keiser P, Sension MG, DeJesus E et al: Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infectious Diseases, 2005; 5: 2
19. Markowitz M, Hill-Zabala C, Lang J et al: Induction with abacavir/lamivudine/ zidovidine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovidine alone in antiretroviral- naïve infected patients. J Acquir Immune Defic Syndr, 2005; 39(3): 257-64
20. De Wit S, Johnson M, Gazzard B et al: Randomised comparison of maintenance therapy with Trizivir [TZV] + efavirenz [EFV] vs TZV in naive HIV-1 infected subjects: TIME study. Program and abstracts of the Seventh International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, United Kingdom. Abstract PL2.4
21. Katlama C, Gazzard B, Mallolas J et al: Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy. AIDS, 2003; 17(12): 185-86
22. Chiesa E, Bini T, Adorni F et al: Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antivir Ther, 2003; 8: 27-35
23. Knobel H, Vallecillo G, Guelar A et al: Simplified therapy with zidovudine, lamivudine, and abacavir for very non-adherent, treatment-failing patients. HIV Clin Trials, 2004; 5(2): 65-73
24. D'Ettorre G, Mastroianni CM, Massetti AP et al: Switching from protease inhibitors to a single class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression. AIDS, 2005; 19: 841-46
25. John M, McKinnon EJ, James IR et al: Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to Combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr, 2003; 33(1): 29-33
26. Moyle GJ, Baldwin C, Langroudi B et al: A 48-week, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr, 2003; 33: 22-28
27. Moyle G, Gazzard BG: Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. AIDS, 2002; 16(7): 1086-87
28. th European AIDS Conference, Warsaw, Poland, October 25-29, 2003
29. van Raalte R, Heere B, Regez R et al: Induction-maintenance strategy re-evaluated: initial boosted-PI in combination with triple NRTI, followed by triple NRTI maintenance. Abs TuPeB4597. XV International AIDS Conference, Bangkok, Thailand, 11-16 July, 2004
30. Ibarra Burrueta O, Martinez Bengoechea MJ, Illaro Uranga A et al: Simplification to lamivudine, zidovudine and abacavir therapy: impact on adherence, clinical outcome, and economic issues. Farm Hosp, 2004; 28(6S1): 27-33
31. Clotet B, Carmena J, Pulido F et al: Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clin Trials, 2004; 5(1): 33-39
32. Lafeuillade A, Clumeck N, Mallolas et al: Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: the Trizal study. HIV Clin Trials, 2003; 4(1): 37-43
33. Fisac C, Fumero E, Crespo M et al: Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS, 2005; 19: 917-25
34. Gallego O, Corral A, de Mendoza C et al: High rate of resistance to antiretroviral drugs among HIV-infected prison inmates. Med Sci Monit, 2003; 9(6): CR269-73